Skip to content

The Clinical Investigation of the Effect of Resistant Starch on the Gastrointestinal Metabolic Function and Microbiota

The Clinical Investigation of the Effect of Resistant Starch on the Gastrointestinal Metabolic Function and Microbiota

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-17012507
Enrollment
Unknown
Registered
2017-08-31
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

control group :control starch

Sponsors

Shanghai Jiao Tong University Affiliaated Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Chinese people; 2. Aged 30-40 years old without statistical differences between genders; 3. BMI: not less than 25kg/m2 4. Subjects with nonalcoholic fatty liver disease diagnosed by ultrasonic examination; 5. Written informed consents must be obtained.

Exclusion criteria

Exclusion criteria: 1. Subjects with diabetes mellitus; 2. Subjects with an alcohol consumption history of more than 20 g per day for men and more than 10 g per day for women; 3. Subjects with acute or chronic gastrointestinal diseases; 4. Pregnant, breastfeeding women or women planning to get pregnant are excluded; 5. Subjects suffering diseases or those who have consumed antibiotics within 3 weeks before participation in the trial; 6. Subjects with hepatic virus infections, autoimmune liver disease, Wilson's disease, or other liver diseases will be ruled out; 7. Subjects with hyperthyroidism or hypothyroidism; 8. Subjects with uncontrolled hypertension; 9. Subjects with coagulation abnormalities; 10. Subjects prescribed with drugs or other Chinese or western medicines (except for regular contraceptives); 11. Subjects expected to have poor compliance; 12. Subjects who have used weight loss medication or program in the previous 4 weeks.

Design outcomes

Primary

MeasureTime frame
Gastrointestinal Metabolic Function and Microbiota;

Secondary

MeasureTime frame
hepatic steatosis;liver enzymes;hepatic pathology;anthropometric indexes;body fat;lipid profiles;biochemical indexes;

Countries

China

Contacts

Public ContactWeiping Jia

Shanghai Jiao Tong University Affiliated Sixth People's Hospital

wpjia@sjtu.edu.cn+86 021-24058924

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026